Literature DB >> 2936869

The mystery of the origin of multiple sclerosis.

W I McDonald.   

Abstract

Our present understanding of the aetiology and pathogenesis of multiple sclerosis is discussed in relation to the views of Sir William Gowers. He perceived that both environmental and genetic factors might be implicated in the aetiology of the disease. Evidence for the former was first reported in 1903, but has become convincing only in the past 20 years; the nature of the environmental factor remains obscure. Evidence for a genetic influence on susceptibility has accumulated since the 1930s, the most compelling coming from the recent Canadian twin study. The number and mode of operation of the genetic factors is still uncertain, but there is evidence for the implication of genetically controlled cellular immune mechanisms in the pathogenesis of the disease. The precise relationship between transient changes in immunological status and the development of new lesions has yet to be defined; magnetic resonance imaging (MRI) promises to play a significant role in this analysis because of its sensitivity in detecting abnormalities in multiple sclerosis. MRI is not in itself specific; it is probable that the similar appearances in multiple sclerosis and cerebral vascular disease both derive at least in part from the influence of astrocytic gliosis on proton content and distribution. The significance of the gliosis is uncertain. Gowers believed that the primary defect in multiple sclerosis lay in the astrocyte. Recent observations on the immunological functions of this cell in vitro suggest that it could be involved early in the pathogenesis of the lesion.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2936869      PMCID: PMC1028675          DOI: 10.1136/jnnp.49.2.113

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  57 in total

1.  MULTIPLE SCLEROSIS AND POLIOMYELITIS.

Authors:  D C POSKANZER; K SCHAPIRA; H MILLER
Journal:  Lancet       Date:  1963-11-02       Impact factor: 79.321

2.  Disseminated sclerosis in South Africa; its relationship to swayback disease and suggested treatment.

Authors:  G DEAN
Journal:  Br Med J       Date:  1949-05-14

3.  Clinical testing of olfaction reassessed.

Authors:  A J Pinching
Journal:  Brain       Date:  1977-06       Impact factor: 13.501

Review 4.  Significance of virus antibodies in multiple sclerosis.

Authors:  M Haire
Journal:  Br Med Bull       Date:  1977-01       Impact factor: 4.291

Review 5.  Epidemiologic contributions to multiple sclerosis: an overview.

Authors:  J F Kurtzke
Journal:  Neurology       Date:  1980-07       Impact factor: 9.910

6.  Multiple sclerosis in the Orkney and Shetland Islands. III: Histocompatibility determinants.

Authors:  D C Poskanzer; P I Terasaki; L B Prenney; J L Sheridan; M S Park
Journal:  J Epidemiol Community Health       Date:  1980-12       Impact factor: 3.710

7.  Multiple sclerosis: immunogenetic analyses of sib-pair double case families. II. Studies on the association of multiple sclerosis with C2, C4, BF, C3, C6, and GLO polymorphisms.

Authors:  R Schröder; H Zander; A Andreas; G Mauff
Journal:  Immunobiology       Date:  1983-03       Impact factor: 3.144

8.  Multiple sclerosis in a migrant population: 2. Half-orientals immigrating in childhood.

Authors:  J F Kurtzke
Journal:  Ann Neurol       Date:  1980-09       Impact factor: 10.422

9.  Cell-type-specific markers for distinguishing and studying neurons and the major classes of glial cells in culture.

Authors:  M C Raff; K L Fields; S I Hakomori; R Mirsky; R M Pruss; J Winter
Journal:  Brain Res       Date:  1979-10-05       Impact factor: 3.252

10.  Lymphocyte subpopulations in patients with multiple sclerosis.

Authors:  A Compston
Journal:  J Neurol Neurosurg Psychiatry       Date:  1983-02       Impact factor: 10.154

View more
  10 in total

1.  Multiple sclerosis: nature or nurture?

Authors:  D C Skegg
Journal:  BMJ       Date:  1991-02-02

2.  Myelin in multiple sclerosis is developmentally immature.

Authors:  M A Moscarello; D D Wood; C Ackerley; C Boulias
Journal:  J Clin Invest       Date:  1994-07       Impact factor: 14.808

3.  Assessment of olfaction in multiple sclerosis: evidence of dysfunction by olfactory evoked response and identification tests.

Authors:  C H Hawkes; B C Shephard; G Kobal
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-08       Impact factor: 10.154

4.  Quantitative magnetic resonance imaging in multiple sclerosis: the effect of high dose intravenous methylprednisolone.

Authors:  J Kesselring; D H Miller; D G MacManus; G Johnson; N M Milligan; N Scolding; D A Compston; W I McDonald
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-01       Impact factor: 10.154

5.  On the mystery of multiple sclerosis.

Authors:  T Fog
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-08       Impact factor: 10.154

6.  The dynamics of multiple sclerosis. The Charcot Lecture.

Authors:  W I McDonald
Journal:  J Neurol       Date:  1993-01       Impact factor: 4.849

7.  Disseminated lesions at presentation in patients with optic neuritis.

Authors:  I E Ormerod; W I McDonald; G H du Boulay; B E Kendall; I F Moseley; A M Halliday; R Kakigi; A Kriss; E Peringer
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-02       Impact factor: 10.154

Review 8.  Therapeutic Value of Single Nucleotide Polymorphisms on the Efficacy of New Therapies in Patients with Multiple Sclerosis.

Authors:  María José Zarzuelo Romero; Cristina Pérez Ramírez; María Isabel Carrasco Campos; Almudena Sánchez Martín; Miguel Ángel Calleja Hernández; María Carmen Ramírez Tortosa; Alberto Jiménez Morales
Journal:  J Pers Med       Date:  2021-04-23

9.  Detection of olfactory dysfunction using olfactory event related potentials in young patients with multiple sclerosis.

Authors:  Fabrizia Caminiti; Simona De Salvo; Maria Cristina De Cola; Margherita Russo; Placido Bramanti; Silvia Marino; Rosella Ciurleo
Journal:  PLoS One       Date:  2014-07-21       Impact factor: 3.240

10.  Effectiveness of amantadine in reducing relapses in multiple sclerosis.

Authors:  G S Plaut
Journal:  J R Soc Med       Date:  1987-02       Impact factor: 18.000

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.